Ashkon Software



CBST - Cubist Pharmaceuticals, Inc.

Cubist Pharmaceuticals, Inc. logo Cubist Pharmaceuticals, Inc. (CBST) was a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for the treatment of serious and life-threatening infections. The company was founded in 1992 and was headquartered in Lexington, Massachusetts.

In December 2014, CBST was acquired by Merck & Co., Inc. for $9.5 billion. At the time of the acquisition, CBST had several marketed products including Cubicin and Zerbaxa, as well as a robust pipeline of antibiotic candidates in development.

Cubicin was a lipopeptide antibiotic used to treat a variety of skin and bloodstream infections caused by Gram-positive bacteria. Zerbaxa was a combination of ceftolozane and tazobactam used to treat complicated urinary tract and intra-abdominal infections caused by Gram-negative bacteria.

The acquisition of CBST by Merck was part of a larger trend in the pharmaceutical industry of consolidation through mergers and acquisitions. Merck saw CBST as a strategic fit to expand its pipeline of antibiotics and strengthen its position in the infectious disease market.

In addition to its antibiotics, CBST was also a leader in the development of diagnostic tests for bacterial infections, including the Xpert MRSA/SA Blood Culture test, which was used to detect MRSA and other Staphylococcus infections in blood samples.

Overall, CBST was an important player in the fight against antibiotic-resistant infections and its acquisition by Merck has helped to strengthen the development of new antibiotics and diagnostic tools for infectiou




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer